Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

LifeArc, one of the UK’s leading medical research charities, has signed a deal to license an ion channel drug discovery programme to Daiichi Sankyo Company, Limited.

The licensing deal successfully concludes a research collaboration between LifeArc, the University of Oxford's Nuffield Department of Clinical Neurosciences and Daiichi Sankyo. 

Small molecules, optimised as part of the programme, are capable of affecting the sensitivity of neurons, show efficacy in treating pain and will undergo further pre-clinical development.

Commenting on the announcement, Dr Justin Bryans, LifeArc’s Executive Director, Drug Discovery, said; 'We’re delighted to have been a part of an exciting collaboration that advanced basic research into a pre-clinical development programme within a major global pharmaceutical company. The success of this project is a testament to fantastic teamwork between all involved.' 

Under the terms of the deal Daiichi Sankyo acquires an exclusive worldwide license to a discovery stage programme of small molecules with the potential to develop into novel treatments for intractable pain.

Jeff Jerman, principal senior scientist and LifeArc project lead said; 'The small molecule drug candidates modulate the ion channel that underpins pain sensing.  LifeArc is using the experience and insight in this ion channel subfamily to explore the therapeutic potential of a range of other channels in the subfamily, including, but not exclusively, for pain.'

Summit Pharmaceuticals International Corporation served as advisor to LifeArc in connection with this transaction.

Similar stories

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

Anaesthetics Research

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

The brain understands relationships in the same way as it understands how to move in space

Integrative Neuroimaging Research

Researchers led by a team at the Wellcome Centre for Integrative Neuroimaging at the University of Oxford have developed a new framework that binds together the way the brain forms maps of space to the way the brain understands relationships of any kind – general mental maps.